Sanifit starts first clinical trial of SNF472 in patients with calciphylaxis
Laboratoris Sanifit has started the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA).
The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis.
